Internship
Computer Science Dual Study
Bachelor of Science
Sanofi
10,001+ employees
Global pharma company; vaccines and R&D
No salary listed
Frankfurt, Germany
Hybrid
Hybrid work may be available up to 60% within Germany, depending on the assignment.
Bachelor's
 Data & Analytics (1) |
|---|
Get referred to Sanofi
See people who can refer or advise you
- A good general or subject-specific university entrance qualification is required.
- Good spoken and written German and English skills are required.
- The candidate should have an interest in mathematics, scientific questions, information technology, and learning and applying artificial intelligence methods.
- The candidate should be comfortable working carefully with large datasets.
- The candidate should demonstrate independent working ability, communication skills, initiative, analytical thinking, adaptability, and willingness to learn.
- The candidate should be able to work effectively with customers and in teams.
- Attend in-person lectures at Provadis Hochschule to acquire theoretical knowledge and apply it in the department several days per week.
- Contribute as a full team member to the management, analysis, and visualization of complex scientific data.
- Apply machine learning and artificial intelligence in data analysis.
- Independently implement digital workflows in coordination with users.
- Use programming and scripting languages to develop workflows and work with databases.
- Support research activities and contribute independently to projects in computer-aided drug discovery.
- Track projects independently from concept development through solution matrices to decision-making.
- Coordinate with stakeholders and users to implement the best solution.
Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Get referred to Sanofi
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales rose 17.8%; Dupixent topped €5.2 billion for the quarter.
- July 30 upgraded 2026 guidance to around 10% sales growth, with higher EPS.
- August 4 MenQuadfi infant approval widens vaccine reach; Nexviazyme's June phase 3 readout strengthens pipeline.
What critics are saying
- Dupixent faces tougher H2 2026 comparisons, threatening growth after the €5.2 billion quarter.
- Cenrifki carries liver injury risk; strict monitoring can slow adoption and invite liability.
- Dupixent concentration and Regeneron's November 2024 lawsuit threaten Sanofi's core growth engine.
What makes Sanofi unique
- Dupixent and partnered launch engine generate repeatable immunology cash flows across geographies.
- Sanofi converted 2026 approvals for Sarclisa Escena, Wayrilz, and Cenrifki into launches.
- Paulo Fontoura's September 1 R&D mandate centralizes translational science and regulatory execution.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Parental Leave
Company News
Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD
InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.
Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.
The US Food and Drug Administration has approved Sanofi's subcutaneous Sarclisa Escena for treating multiple myeloma, making it the first anticancer treatment administered through an on-body injector. The therapy uses Enable Injections' CirCLIQ device, which delivers the drug automatically with a retractable 30g needle. The approval was supported by the IRAKLIA phase 3 study, which demonstrated that Sarclisa Escena delivered via the on-body injector provided similar efficacy and safety compared to intravenous infusion, with significantly shorter treatment time and fewer infusion-related reactions. The study showed a 71.1% objective response rate in patients with relapsed or refractory multiple myeloma. More than 70,000 patients worldwide have been treated with Sarclisa-based regimens. The on-body injector aims to reduce physical burden on healthcare providers whilst offering patients greater convenience during treatment.
Sanofi has appointed Paulo Fontoura as Executive Vice President and Global Head of Research & Development Pharma, effective 1 September. Based in Paris, Fontoura will oversee the company's innovation engine, spanning research, translational medicine, clinical development, and regulatory affairs. He succeeds Dr Houman Ashrafian, who is leaving to pursue new opportunities. Fontoura brings over 25 years of experience across academic medicine, translational science, and pharmaceutical innovation. The appointment comes as Sanofi drives an R&D transformation whilst progressing its pipeline across multiple therapeutic areas. Separately, MacroGenics confirmed it will receive $24.5 million in regulatory milestone payments from Sanofi following FDA accelerated approval of TZIELD to delay decline in endogenous insulin production in children. Sanofi is a global biopharmaceutical company focusing on immunology, rare diseases, and oncology.